Abstract:Plasmodium vivax serological exposure markers (SEMs) have emerged as promising tools for the actionable surveillance and implementation of targeted interventions to accelerate malaria elimination. To determine the dynamic profiles of SEMs in current and past P . vivax infections, we screened and selected 11 P . vivax proteins from 210 putative proteins using protein arrays, with a set of serum samples obtained from patients with acute P . vivax and documented past P . vivax infections. Then we used a murine protein immune model to initially investigate the humoral and memory B cell response involved in the generation of long-lived antibodies. We show that of the 11 proteins, especially C-terminal 42-kDa region of P . vivax merozoite surface protein 1 (PvMSP1-42) induced longer-lasting long-lived antibodies, as these antibodies were detected in individuals infected with P . vivax in the 1960-1970s who were not re-infected until 2012. In addition, we provide a potential mechanism for the maintenance of long-lived antibodies after the induction of PvMSP1-42. The results indicate that PvMSP1-42 induces more CD73 + CD80 + memory B cells (MBCs) compared to P . vivax GPI-anchored micronemal antigen (PvGAMA), allowing IgG anti-PvMSP1-42 antibodies to be maintained for a long time. P . vivax serological exposure markers (SEMs) that reflect exposure to blood-stage P . vivax parasites, could play an important role in assessing progress towards malaria elimination. Serological surveillance can be a useful tool for identifying areas of high transmission intensity or hidden asymptomatic reservoirs, especially as malaria transmission declines. These immune responses can persist long after the clearance of blood-stage infection, making antibodies valuable markers for both past exposure and current infection status. Furthermore, gaining a better understanding of the host immune response to malaria, particularly regarding the induction and maintenance of high levels of circulating antibodies, is crucial for effective serological surveillance efforts. Using serum obtained in 2007 or 2012 from patients with acute P . vivax infection, 5-year, 12-year and 30-year recovery of P . vivax -infected patients we provide evidence that PvMSP1-42 induces long-lived anti-PvMSP1-42 antibodies. Then we used a murine protein immune model, show that more CD73 + CD80 + memory B cells, allowing IgG anti-PvMSP1-42 antibodies to be maintained for a long time (Fig 1). The results of this study represent an important step forward in our understanding of the host immune response to P . vivax blood stages, including the induction and maintenance of high levels of circulating antibodies. These findings may have important implications for the development of effective serological surveillance tools.

Functional and immunological mapping of domains of the reticulocyte binding protein, Plasmodium vivax PvRBP2a

Comparison of total immunoglobulin G antibody responses to different protein fragments of Plasmodium vivax Reticulocyte binding protein 2b

Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain

PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial

Untangling population structure and genetic diversity of reticulocyte binding protein 2b (PvRBP2b) erythrocytic stage vaccine candidate in worldwide Plasmodium vivax isolates

Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45

An Immunomics Approach for the Analysis of Natural Antibody Responses to Plasmodium Vivax Infection.

Characterization of T and B cell epitopes in PvCyRPA by studying the naturally acquired immune response in Brazilian Amazon communities

Profiling the antibody response of humans protected by immunization with Plasmodium vivax radiation-attenuated sporozoites

Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial

Natural genetic diversity of the DBL domain of a novel member of the plasmodium vivax erythrocyte binding-like proteins (EBP2) in the Amazon rainforest

Dynamics of IgM and IgG Antibody Response Profile against Linear B-Cell Epitopes from Exoerythrocytic (CelTOS and TRAP) and Erythrocytic (CyRPA) Phases of Plasmodium vivax: Follow-Up Study

Exploring the genetic diversity pattern of Pv EBP/DBP2: A promising candidate for an effective Plasmodium vivax vaccine

Genetic diversity, natural selection and haplotype grouping of Plasmodium vivax Duffy-binding protein genes from eastern and western Myanmar borders

Transferrin receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax

Plasmodium vivax serological exposure markers: PvMSP1-42-induced humoral and memory B-cell response generates long-lived antibodies

Cross-reactivity of r Pvs 48/45, a recombinant Plasmodium vivax protein, with sera from Plasmodium falciparum endemic areas of Africa

A systematic analysis of the human immune response to Plasmodium vivax

Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites: Naturally Acquired Humoral Immune Response and B-Cell Epitope Mapping in Brazilian Amazon Inhabitants

Characterization of merozoite-specific thrombospondin-related anonymous protein (MTRAP) in Plasmodium vivax and P. knowlesi parasites

Identification of the Recombinant Plasmodium vivax Surface-Related Antigen as a Possible Immune Evasion Factor Against Human Splenic Fibroblasts by Targeting ITGB1